^
Association details:
| Biomarker: | AR splice variant 7 |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Xtandi (enzalutamide) (Androgen receptor inhibitor) + HSK38008 (AR-V7 degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LB262 / 14 - HSK38008: An oral AR-V7 degrader for metastatic castration-resistant prostate cancer
Published date:
03/15/2023
Excerpt:
HSK38008 significantly inhibit the cell proliferation in AR-V7 positive cell line, e.g., 22RV1, but weak antiproliferation in AR and ARV7 positive cell line such as VCAP However, when combination with enzalutamide there is synergistic effect for the anti-proliferation in VCAP.
